First child dosed in Neurotech's Phase 3 cannabis trial for autism

Latest News

Neurotech International has begun dosing children in the pivotal Phase 3 trial of its cannabis-based autism drug. 

The Melbourne company dosed the first patient in its Beyond Harmony study of NTI164 on 21 September. All six sites across Victoria, Queensland, New South Wales, Tasmania and Western Australia are now open. The randomised, double blind, placebo-controlled trial will enrol up to 200 children and uses an adaptive design. It will measure core autism symptoms and look at the neuroinflammatory pathways linked to the disorder.

More than 300 parents and carers have asked about enrolling their children since the trial was covered in the media. Neurotech says that gives it confidence it can recruit on schedule.

The trial builds on the 54-patient Phase II/III Harmony study. Neurotech says that study produced clinically meaningful and statistically significant results with a favourable safety profile. The findings have since been published in Neurotherapeutics under the title "NTI164, a novel medicinal cannabis extract, improves core symptoms of autism spectrum disorder".

Neurotech also cleared hurdles in the United States. The US Food and Drug Administration approved its Investigational New Drug application, which opens a path to a US dosing study that would complement the Australian trial. The US Patent and Trademark Office also allowed two patent applications. One covers using NTI164 to reduce neuroinflammation and the other covers using it to treat autism.

To pay for the work, Neurotech raised about $4.5 million through a placement at 1.4 cents a share. About $0.4 million of that still needs shareholder approval. It also borrowed $3.15 million at 16 per cent interest against expected research and development tax refunds.

The company says it "anticipates to be fully funded through to the top line data readout of the Phase 3 clinical trial."

Operating outflows more than doubled to $4.19 million in the September quarter, almost all of it spent on research and development. Cash rose to $5.2 million, but Neurotech estimated it had just 1.24 quarters of funding at that rate.

"The Company paid a large amount of clinical trial initiation fees in Q1FY27 which were one off payments." It is also counting on the rest of the placement and a tax refund due in the December quarter, after loan repayments.

"The Company continues to monitor its funding position and expenditure requirements closely," it said.